British Sarcoma Group Annual Conference 2026
- Title: The Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomised, Registrational, Phase 2 ChonDRAgon Study
- Oral presentation
- Lead author: Robin Jones
